Exploring the Safety and Efficacy of Direct Oral Anticoagulants (DOACs) in Vulnerable Patient Populations: Brooklyn Hospital Only
May 10, 2024
Target Audience
All pharmacists
Learning Objectives
At the completion of this activity, the participant will be able to:
- Describe the mechanism, dosing, indications, adverse drug reactions of DOACs
- Evaluate recommendations provided by guidelines including 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation and American Society of Hematology Treatment of VTE or Pulmonary Embolism regarding DOACs usage in vulnerable patient populations
- Analyze literature utilizing DOACs in individuals with extreme weight, advanced age, or kidney impairment
- Summarize the safety and efficacy of utilizing DOACs in the vulnerable patient population based on the primary literature
ZOOM or Brooklyn Hospital
United States
Pauletta Lazarevskiy, PGY-1 Pharmacy Resident, PharmD.
Pauletta Lazarevskiy graduated from the Arnold and Marie Schwartz College of Pharmacy and Health Sciences at Long Island University in 2023 and is a PGY1 pharmacy resident at The Brooklyn Hospital Center. Starting this July, she will begin her Ambulatory Care PGY-2 at The Brooklyn Hospital Center.
ACPE UAN 0042-0000-24-036-L01-P
Available Credit
- 1.00 ACPEThe Arnold & Marie Schwartz College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.